DC
KYTX icon

Diametric Capital’s Kyverna Therapeutics KYTX Stock Holding History

Diametric Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Buy
+16,067
New +$134K 0.04% 405
2024
Q2 		– Sell
-9,300
Closed -$231K – 485
2024
Q1 		$231K Buy
+9,300
New +$259K 0.13% 221

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Diametric Capital's KYTX Position: Q1 2026 in Review

Diametric Capital opened a new position in Kyverna Therapeutics (KYTX) in Q1 2026: 16,067 shares worth $139K. The stake represents 0.04% of the portfolio and ranks #405 among its holdings. This is a return to the name: Diametric Capital previously reported a position in KYTX as recently as Q1 2024.

Diametric Capital first reported a position in KYTX in Q1 2024 and has held it in 2 quarters since. The position peaked at $231K in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Diametric Capital held 16,067 shares of Kyverna Therapeutics worth $139K as of Q1 2026.
  • Kyverna Therapeutics was a new Diametric Capital position in Q1 2026.
  • Kyverna Therapeutics made up 0.04% of Diametric Capital's portfolio in Q1 2026, its #405 holding.
  • Diametric Capital first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • Diametric Capital's Kyverna Therapeutics position peaked at $231K in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.